Claire Arnaud

Dr. Claire Arnaud

University Grenoble Alpes, Inserm, CHU Grenoble Alpes, HP2, Grenoble, France
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2005 in Nature
Verified
Journal Article
Closed access
SSSabine Steffens
Sabine Steffens
NVNiels R. Veillard
Niels R. Veillard
Claire ArnaudClaire Arnaud
Claire Arnaud
GPGraziano Pelli
Graziano Pelli
FBFabienne Burger
Fabienne Burger
FMFrançois Mach
François Mach

1 February 2007 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
VBVincent Braunersreuther
Vincent Braunersreuther
AZAlma Zernecke
Alma Zernecke
Claire ArnaudClaire Arnaud
Claire Arnaud
ELElisa A. Liehn
Elisa A. Liehn
SSSabine Steffens
Sabine Steffens
CWChristian Weber
Christian Weber
Objective—Chemokines and their receptors are crucially involved in the development of atherosclerotic lesions by directing monocyte and T cell recruitment. The CC-chemokine receptors 1 (CCR1) and 5 (CCR5) expressed on these cells bind chemokines implicated in atherosclerosis, namely CCL5/RANTES. Although general blockade of CCL5 receptors reduces atherosclerosis, specific roles of CCR1 and CCR5 have not been unequivocally determined.Methods and Results—We provide two independent lines of investigation to dissect the effects of Ccr1 and Ccr5 deletion in apolipoprotein E–deficient (ApoE−/−) mice in a collaboration between Aachen/Germany and Geneva/Switzerland. Different strains of ApoE−/−Ccr5−/−mice, ApoE−/−Ccr1−/−mice or respective littermates, were fed a high-fat diet for 10 to 12 weeks. Plaque areas were quantified in the aortic roots and thoracoabdominal aortas. Concordantly, both laboratories found that lesion formation was reduced in ApoE−/−Ccr5−/−mice. Plaque quality and immune cells were assessed by immunohistochemistry or mRNA analysis. Whereas lesional macrophage content, aortic CD4, and Th1-related Tim3 expression were reduced, smooth muscle cell (SMC) content and expression of interleukin-10 in plaques, lesional SMCs, and splenocytes were elevated. Protection against lesion formation by Ccr5 deficiency was sustained over 22 weeks of high-fat diet or over 26 weeks of chow diet. Conversely, plaque area, T cell, and interferon-γ content were increased in ApoE−/−Ccr1−/−mice.Conclusion—Genetic deletion of Ccr5 but not Ccr1 in ApoE−/−mice protects from diet-induced atherosclerosis, associated with a more stable plaque phenotype, reduced mononuclear cell infiltration, Th1-type immune responses, and increased interleukin-10 expression. This corroborates CCR5 as a promising therapeutic target.

1 June 2005 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
Claire ArnaudClaire Arnaud
Claire Arnaud
FBFabienne Burger
Fabienne Burger
SSSabine Steffens
Sabine Steffens
NVNiels R. Veillard
Niels R. Veillard
TNTuan Huy Nguyen
Tuan Huy Nguyen
FMFrançois Mach
François Mach
Objectives— Besides its predictive role in determining cardiovascular risk, C-reactive protein (CRP) may exert direct proatherogenic effects through proinflammatory properties. CRP is mainly produced by hepatocytes in response to interleukin-6 (IL-6) and is then released into the systemic circulation. 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase inhibitors, or statins, significantly reduce cardiovascular events and mortality in patients with or without coronary artery disease and reduce plasma CRP levels in humans. However, the mechanism by which statins reduce plasma CRP levels remains unknown. Methods and Results— In this study, we report that statins limit both protein and RNA levels of IL-6-induced CRP in human hepatocytes. These effects are reversed by l -mevalonate and mimicked by an inhibitor of the geranylgeranyltransferase. IL-6–induced CRP production requires the binding of IL-6 to its cognate receptors, which results in activation and phosphorylation of the transcription factor STAT3. We provide evidence that statins reduce this IL-6–induced phosphorylation of STAT3 in hepatocytes. Conclusion— These results demonstrate that statins reduce IL-6–induced CRP production directly in hepatocytes via inhibition of protein geranylgeranylation. We further show that statins act via inhibition of STAT3 phosphorylation. These findings furnish new evidence for direct antiinflammatory properties of statins and provide new mechanistic insight into their clinical benefits.

19 April 2017 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
AMAoife M. Murphy
Aoife M. Murphy
ATAmandine Thomas
Amandine Thomas
SCSophie J. Crinion
Sophie J. Crinion
BKBrian D. Kent
Brian D. Kent
Murtaza TambuwalaMurtaza Tambuwala
Murtaza Tambuwala
SRSilke Ryan
Silke Ryan
Obstructive sleep apnoea (OSA) is increasingly associated with insulin resistance. The underlying pathophysiology remains unclear but intermittent hypoxia (IH)-mediated inflammation and subsequent dysfunction of the adipose tissue has been hypothesised to play a key role.We tested this hypothesis employing a comprehensive translational approach using a murine IH model of lean and diet-induced obese mice, an innovative IH system for cell cultures and a tightly controlled patient cohort.IH led to the development of insulin resistance in mice, corrected for the degree of obesity, and reduced insulin-mediated glucose uptake in 3T3-L1 adipocytes, associated with inhibition of the insulin-signalling pathway and downregulation of insulin-receptor substrate-1 mRNA. Providing mechanistic insight, IH induced a pro-inflammatory phenotype of visceral adipose tissue in mice with pro-inflammatory M1 macrophage polarisation correlating with the severity of insulin resistance. Complimentaryin vitroanalysis demonstrated that IH led to M1 polarisation of THP1-derived macrophages. In subjects without comorbidities (n=186), OSA was independently associated with insulin resistance. Furthermore, we found an independent correlation of OSA severity with the M1 macrophage inflammatory marker sCD163.This study provides evidence that IH induces a pro-inflammatory phenotype of the adipose tissue, which may be a crucial link between OSA and the development of insulin resistance.

30 September 2008 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
PLPatrick LEVY
Patrick LEVY
JPJean-Louis Pepin
Jean-Louis Pepin
Claire ArnaudClaire Arnaud
Claire Arnaud
RTRenaud Tamisier
Renaud Tamisier
JBJ-C. Borel
J-C. Borel
CRC. Ribuot
C. Ribuot
There are three major types of sleep-disordered breathing (SDB) with respect to prevalence and health consequences,i.e.obstructive sleep apnoea syndrome (OSAS), Cheyne–Stokes respiration and central sleep apnoea (CSR-CSA) in chronic heart failure, and obesity hypoventilation syndrome (OHS). In all three conditions, hypoxia appears to affect body functioning in different ways. Most of the molecular and cellular mechanisms that occur in response to SDB-related hypoxia remain unknown.In OSAS, an inflammatory cascade mainly dependent upon intermittent hypoxia has been described. There is a strong interaction between haemodynamic and inflammatory changes in promoting vascular remodelling. Moreover, during OSAS, most organ, tissue or functional impairment is related to the severity of nocturnal hypoxia. CSR-CSA occurring during heart failure is primarily a consequence of cardiac impairment. CSR-CSA has deleterious consequences for cardiac prognosis and mortality since it favours sympathetic activation, ventricular ectopy and atrial fibrillation. Although correction of CSR-CSA seems to be critical, there is a need to establish therapy guidelines in large randomised controlled trials.Finally, OHS is a growing health concern, owing to the worldwide obesity epidemic and OHS morbidities. The pathophysiology of OHS remains largely unknown. However, resistance to leptin, obesity and severe nocturnal hypoxia lead to insulin resistance and endothelial dysfunction. In addition, several adipokines may be triggered by hypoxia and explain, at least in part, OHS morbidity and mortality.Overall, chronic intermittent hypoxia appears to have specific genomic effects that differ notably from continuous hypoxia. Further research is required to fully elucidate the molecular and cellular mechanisms.

1 September 2006 in Atherosclerosis
Verified
Journal Article
Closed access
NVNiels R. Veillard
Niels R. Veillard
VBVincent Braunersreuther
Vincent Braunersreuther
Claire ArnaudClaire Arnaud
Claire Arnaud
FBFabienne Burger
Fabienne Burger
GPGraziano Pelli
Graziano Pelli
FMFrançois Mach
François Mach